Shanghai Henlius Biotech, Inc. (2696.HK)

HKD 40.35

(3.59%)

Total Liabilities Summary of Shanghai Henlius Biotech, Inc.

  • Shanghai Henlius Biotech, Inc.'s latest annual total liabilities in 2023 was 7.71 Billion CNY , up 5.81% from previous year.
  • Shanghai Henlius Biotech, Inc.'s latest quarterly total liabilities in 2024 Q2 was 7.4 Billion CNY , down 0.0% from previous quarter.
  • Shanghai Henlius Biotech, Inc. reported annual total liabilities of 7.28 Billion CNY in 2022, up 49.46% from previous year.
  • Shanghai Henlius Biotech, Inc. reported annual total liabilities of 4.87 Billion CNY in 2021, up 50.48% from previous year.
  • Shanghai Henlius Biotech, Inc. reported quarterly total liabilities of 7.4 Billion CNY for 2024 Q2, down 0.0% from previous quarter.
  • Shanghai Henlius Biotech, Inc. reported quarterly total liabilities of 7.7 Billion CNY for 2023 Q1, up 5.69% from previous quarter.

Annual Total Liabilities Chart of Shanghai Henlius Biotech, Inc. (2023 - 2017)

Historical Annual Total Liabilities of Shanghai Henlius Biotech, Inc. (2023 - 2017)

Year Total Liabilities Total Liabilities Growth
2023 7.71 Billion CNY 5.81%
2022 7.28 Billion CNY 49.46%
2021 4.87 Billion CNY 50.48%
2020 3.24 Billion CNY 70.6%
2019 1.89 Billion CNY 46.99%
2018 1.29 Billion CNY -17.19%
2017 1.56 Billion CNY 0.0%

Peer Total Liabilities Comparison of Shanghai Henlius Biotech, Inc.

Name Total Liabilities Total Liabilities Difference
Uni-Bio Science Group Limited 152.81 Million HKD -4946.048%
CK Life Sciences Int'l., (Holdings) Inc. 7.05 Billion HKD -9.253%